Zomedica reports record FY2023 revenue $25.2M (+33% YoY); net loss $34.5M; guides FY2024 $31-35M

Zomedica Corp.

2024-Q2 EPS reported -$0.03 vs consensus $0.00 ▼ miss (-3400000.0%)

Q4 2023 revenue $7.3M (+19% YoY); FY2023 revenue $25.2M (+33% YoY), driven by Diagnostics (+252%) and Therapeutic Devices (+28%).
Gross margin 69% for FY2023; consumable revenue $16.4M (+41% YoY), 65% of total revenue.
Net loss $34.5M ($0.035/share) vs $17.0M in FY2022; Adjusted Non-GAAP EBITDA loss $12.8M.
Cash and securities $100.5M at Dec 31, 2023; reiterated FY2024 revenue guidance $31-35M.
Acquisitions of SMP (VetGuardian) and Qorvo Biotechnologies in 2023; launched TRUVIEW and new assays.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.